Dr. Laura Esserman, MD
Claim this profileUniversity of California, San Francisco
Studies Breast Cancer
Studies Vulval Intraepithelial Neoplasia
9 reported clinical trials
45 drugs studied
Area of expertise
1Breast Cancer
Stage III
Stage II
ER positive
2Vulval Intraepithelial Neoplasia
ER positive
PR positive
Affiliated Hospitals
Clinical Trials Laura Esserman, MD is currently running
Risk-Based Screening
for Breast Cancer
Most physicians still use a one-size-fits-all approach to breast screening in which all women, regardless of their personal history, family history or genetics (except BRCA carriers) are recommended to have annual mammograms starting at age 40. Mammograms benefit women by detecting cancers early when they are easier to treat, but they are not perfect. Recent news stories have discussed some of the potential harms: large numbers of positive results that cause stressful recalls for additional mammograms and biopsies. With the current screening approach, half of the women who undergo annual screening for ten years will have at least one false positive biopsy. Potentially more important are cancer diagnoses for growths that might never come to clinical attention if left alone (called "overdiagnosis"). This can lead to unnecessary treatment. Even more concerning is evidence that up to 20% of breast cancers detected today may fall into the category of "overdiagnosis." This study compares annual screening with a risk-based breast cancer screening schedule, based upon each woman's personal risk of breast cancer. The investigators have designed the study to be inclusive of all, so that even women who might be nervous about being randomly assigned to receive a particular type of care (a procedure that is typical in clinical studies) will still be able to participate by choosing the type of care they receive. For participants in the risk-based screening arm, each woman will receive a personal risk assessment that includes her family and medical history, breast density measurement and tests for genes (mutations and variations) linked to the development of breast cancer. Women who have the highest personal risk of developing breast cancer will receive more frequent screening, while women with a lower personal risk would receive less frequent screening. No woman will be screened less than is recommended by the USPSTF breast cancer screening guidelines. If this study is successful, women will gain a realistic understanding of their personal risk of breast cancer as well as strategies to reduce their risk, and fewer women will suffer from the anxiety of false positive mammograms and unnecessary biopsies. The investigators believe this study has the potential to transform breast cancer screening in America.
Recruiting1 award N/A4 criteria
Various Treatments
for Critically Ill COVID-19 Patients
The goal of this project is to rapidly screen promising agents, in the setting of an adaptive platform trial, for treatment of critically ill COVID-19 patients. In this phase 2 platform design, agents will be identified with a signal suggesting a big impact on reducing mortality and the need for, as well as duration, of mechanical ventilation.
Recruiting2 awards Phase 24 criteria
More about Laura Esserman, MD
Clinical Trial Related8 years of experience running clinical trials · Led 9 trials as a Principal Investigator · 7 Active Clinical TrialsTreatments Laura Esserman, MD has experience with
- Risk-based Breast Cancer Screening Schedule
- Amcenestrant + Abemaciclib
- Amcenestrant + Letrozole
- Cemiplimab
- Cemiplimab Plus REGN3767
- Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) + Carboplatin With Or Without Trastuzumab
Breakdown of trials Laura Esserman, MD has run
Breast Cancer
Vulval Intraepithelial Neoplasia
Parotid Gland Cancer
Ductal Carcinoma In Situ
Lobular Carcinoma in Situ
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
What does Laura Esserman, MD specialize in?
Is Laura Esserman, MD currently recruiting for clinical trials?
Are there any treatments that Laura Esserman, MD has studied deeply?
What is the best way to schedule an appointment with Laura Esserman, MD?
What is the office address of Laura Esserman, MD?
Is there any support for travel costs?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.